Anna Maria Della Corte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Maria Della Corte has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Galdiero
CEINGE Biotecnologie Avanzate Franco Salvatore (Italy), Naples, Italy, Italy
1 shared publication - Angela Bertolini
Hematology and Transplant Center University Hospital “San Giovanni di Dio e Ruggi d'Aragona” Salerno Italy
1 shared publication - Anna Maria Sessa
Hematology and Transplant Center University Hospital “San Giovanni di Dio e Ruggi d'Aragona” Salerno Italy
1 shared publication - Barbara Izzo
Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II” and CEINGE Advanced Biotechnology “Franco Salvatore”, 80131 Naples, Italy
1 shared publication - Bianca Serio
Hematology and Transplant Center University Hospital “San Giovanni di Dio e Ruggi d'Aragona” Salerno Italy
1 shared publication - Carmine Selleri
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi, Italy
1 shared publication
Latest Publications
- Open Access
- 27 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 729-741
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition
Background: Splicing modifications, genomic instability, and hypomethylation are central mechanisms promoting myelodysplasia and acute myeloid leukemia (AML). In this real‐life retrospective study, to elucidate pathophysiology of clonal hemopoiesis in hematological malignancies, we investigated clinical significance of mutations in leukemia‐related genes of known pathogenetic significance and of variants of uncertain clinical significance (VUS) in a cohort of patients with MDS and AML.Methods: A total of 59 consecutive subjects diagnosed with MDS, 48 with AML, and 17 with clonal cytopenia with unknown significance were screened for somatic mutations in AML‐related genes by next‐generation sequencing.Results: We showed that TET2, SETBP1, ASXL1, EZH2, RUNX1, SRSF2, DNMT3A, and IDH1/2 were commonly mutated. MDS patients also showed a high genetic complexity, especially for SETBP1. Moreover, the presence of SETBP1 wild‐type or two or more simultaneous VUS variants identified a subgroup of AML and MDS patients with better outcome, while the presence of single SETBP1 VUS variant was related to a worse prognosis, regardless TET2 mutational status.Conclusions: In conclusions, we linked both pathogenic and VUS variants in AML‐related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.
- 27 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 729-741
Open AccessSubclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition
Background: Splicing modifications, genomic instability, and hypomethylation are central mechanisms promoting myelodysplasia and acute myeloid leukemia (AML). In this real‐life retrospective study, to elucidate pathophysiology of clonal hemopoiesis in hematological malignancies, we investigated clinical significance of mutations in leukemia‐related genes of known pathogenetic significance and of variants of uncertain clinical significance (VUS) in a cohort of patients with MDS and AML.Methods: A total of 59 consecutive subjects diagnosed with MDS, 48 with AML, and 17 with clonal cytopenia with unknown significance were screened for somatic mutations in AML‐related genes by next‐generation sequencing.Results: We showed that TET2, SETBP1, ASXL1, EZH2, RUNX1, SRSF2, DNMT3A, and IDH1/2 were commonly mutated. MDS patients also showed a high genetic complexity, especially for SETBP1. Moreover, the presence of SETBP1 wild‐type or two or more simultaneous VUS variants identified a subgroup of AML and MDS patients with better outcome, while the presence of single SETBP1 VUS variant was related to a worse prognosis, regardless TET2 mutational status.Conclusions: In conclusions, we linked both pathogenic and VUS variants in AML‐related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.